Mesoblast Shares Today’s ASX 200 Laggard, As Growth Sells Down

Mesoblast shares (ASX: MSB) finished today’s session as the worst performer in the ASX 200, closing 6.3% lower at A$2.23 as a broad retreat from growth and healthcare names continues what has been a choppy year for holders.

MSB bulls had been attempting to push the stock through to flip resistance at A$2.50 in recent sessions, but as the breakout failed, the stock has now pulled back 11% over the past 12 trading sessions. After plenty of moves in both directions, shares sit 20% below their mid-July high of A$2.77, and are down 19.49% year-to-date, yet 18% off from the late June lows. This has not been one for the faint of heart to follow.

Why are Mesoblast shares down?

Today’s action was not limited to MSB, with healthcare, technology and growth stocks all stuttering to start the week, with Pro Medicus falling 2.86%, WiseTech Global dropping 3.79% and Xero losing 3.94%. The S&P/ASX 200 Healthcare Index (XIJ) fell 2.6% to start the week and is now 11% lower over two weeks, as markets begin pricing in the possibility of interest rate hikes at the Reserve Bank of Australia’s September meeting.

Rising rate expectations tend to hit long-duration biotech names hardest, as higher discount rates compress the present value of future cash flows, a dynamic that weighs disproportionately on companies like Mesoblast that are still scaling toward sustainable profitability.

Recent fundamentals

The pullback follows Mesoblast’s preliminary FY26 results, released in late August, which marked the company’s formal transition from a clinical-stage biotech to a commercial operation. Full-year net revenue came in between US$115 million and US$120.25 million, a dramatic increase from US$17.2 million in FY25, driven by the US rollout of Ryoncil (remestemcel-L) for pediatric steroid-refractory acute graft-versus-host disease. Fourth-quarter Ryoncil net revenue reached US$36 million, representing 20% quarter-on-quarter growth.

However, the bottom line remains firmly in deficit. Mesoblast reported a net loss of US$57.5 million for the year, and post-results analyst revisions have pushed back the profitability timeline. Consensus FY2027 revenue estimates were trimmed from US$221 million to US$195 million, while statutory earnings expectations swung from a projected profit of US$0.02 per share to a loss of US$0.01 per share. The balance sheet held US$103 million in cash as of June 30, 2026, supplemented by a US$50 million debt refinancing facility.

On the pipeline front, the company announced on August 17 that all 350 patients in its pivotal Phase 3 MSB-DR004 trial of rexlemestrocel-L for chronic low back pain had completed treatment. The trial carries FDA RMAT designation, enabling priority review and a rolling BLA pathway, with top-line 12-month data expected in mid-2027.

What Lay Ahead

Bell Potter retained its buy rating and a A$4.45 price target following the results, citing double-digit revenue growth at Ryoncil and what it characterised as significant asymmetric upside across the heart failure and chronic back pain pipelines. Notably, chief executive Dr Silviu Itescu purchased shares on-market in July 2026, a move generally read as a signal of management’s confidence in the company’s trajectory.

The near-term setup presents a clear tension, as fundamentally, Mesoblast has never been in a stronger commercial position. Revenue is growing at a rapid clip, the Ryoncil franchise is expanding into larger indications, and the Phase 3 back pain program targeting a US market estimated at more than US$10 billion annually has cleared a major execution hurdle with treatment completion.

With the next major clinical readout not due until mid-2027, the stock enters a multi-quarter period in which price action will likely be dictated more by macro conditions than company milestones. The wide A$2-A$2.50 range may prove tough to break in the absence of major updates, with the stock now just 2 cents above the same point this time last year.

Bull Case: